<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McMahon, Maureen</style></author><author><style face="normal" font="default" size="100%">Skaggs, Brian J.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rethinking Cardiovascular Screening in Systemic Lupus Erythematosus</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">589-591</style></pages><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.2026-0136</style></doi><volume><style face="normal" font="default" size="100%">53</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Cardiovascular disease (CVD) remains a leading cause of mortality in patients with systemic lupus erythematosus (SLE). Decades of data have established that patients with SLE experience myocardial infarctions and strokes at rates far exceeding those of the general population, often at strikingly young ages.1 The increased prevalence of CVD in younger patients was confirmed in the Manhattan Lupus Surveillance Program, which found the prevalence ratio for cardiovascular events was 6.4 in younger patients with SLE aged 20-49 years and 2.2 in patients with SLE aged 50 years and older, compared with age-stratified national estimates.2 This risk is even greater in patients with a history of lupus nephritis.3 Expert consensus guidelines recommend that high-risk patients with SLE be treated with statins in a manner similar to at-risk general population patients.4 Unfortunately, current screening tools to identify at-risk patients with SLE who need prevention-targeted strategies continue to fall short.In this issue of The Journal of Rheumatology, the study by Patel et al adds to a growing body of evidence that conventional cardiovascular risk calculators, including the widely used Atherosclerotic CV Disease (ASCVD) Risk Score, are inadequate for patients with SLE.5 Previous studies demonstrated risk calculators that factor an SLE diagnosis into account, such as the QRISK3 or the modified Framingham Risk Score, do not fully capture the increased risk in patients with SLE.6 The recently developed SLE-specific CV risk (SLECRISK; formerly SLE Cardiovascular Risk Equation [SLECRE]) incorporates both general cardiovascular risk factors and SLE-specific risks including disease duration, corticosteroid and hydroxychloroquine use, disease activity, renal involvement, and the presence of antiphospholipid antibodies. … Address correspondence to Dr. M. McMahon, UCLA Medical Center, Division of Rheumatology, 32-59 Rehab Center, 1000 Veteran Avenue, Los Angeles, CA 90095, USA. Email: mmcmahon{at}mednet.ucla.edu.</style></abstract></record></records></xml>